Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Maria Joao Baptista, PhD PharmD, Neil Basumallik, Sarah E. M. Herman, PhD, Erika M. Cook, Inhye E. Ahn, MD, Adrian Wiestner, MD, Clare C. Sun, MD

Blood (2018) 132 (Supplement 1): 238.

https://doi.org/10.1182/blood-2018-99-109847

Published: 2018

Journal Articles

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Inhye E. Ahn, MD, Xin Tian, Maher Albitar, MD, Sarah E. M. Herman, PhD, Erika M. Cook, Susan Soto, Wanlong Ma, David Ipe, L. Claire Tsao, Mei Cheng, James P. Dean, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 186.

https://doi.org/10.1182/blood-2018-99-110326

Published: 2018

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD

Blood (2018) 132 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2018-99-110391

Published: 2018

Journal Articles

Integrated Genomic and Proteomic Analysis of Murine CLL-like Cells Reveals SF3B1 Mutation to Impact DNA Damage Response and BCR Signaling

Lili Wang, MDPhD, Shanye Yin, PhD, Aina zurita Martinez, Fara Faye Regis, BS, Angela Brooks, PhD, Sarah E. M. Herman, PhD, Elisa Ten Hacken, PhD, Esther Obeng, MD PhD, Dean Campagna, BS, Mark D. Fleming, MD DPhil, Benjamin L. Ebert, MDPhD, Adrian Wiestner, MD, Ignaty Leshchiner, PhD, Gad Getz, PhD, Ruben D. Carrasco, MD PhD, Catherine J. Wu, MD

Blood (2018) 132 (Supplement 1): 947.

https://doi.org/10.1182/blood-2018-99-117691

Published: 2018

Journal Articles

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic— TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Christian Brieghel, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Adrian Wiestner, MD, Carsten Utoft Niemann

Blood (2018) 132 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2018-99-114472

Published: 2018

Journal Articles

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clare Sun, MD, Camilia Soof, BS, Alankrita Taneja, MD, Sarah E. M. Herman, PhD, Erika Cook, BA, Kyle Udd, BA, Haiming Chen, MD PhD, Eric Sanchez, BA, Xin Tian, PhD, Inhye E. Ahn, MD, James R Berenson, MD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 4031.

https://doi.org/10.1182/blood.V130.Suppl_1.4031.4031

Published: 2017

Journal Articles

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

Clare Sun, MD, Delong Liu, PhD, Nakhle S. Saba, MD, Sarah E. M. Herman, PhD, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 1718.

https://doi.org/10.1182/blood.V130.Suppl_1.1718.1718

Published: 2017

Journal Articles

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

Hannah R. Robinson, BA, Junpeng Qi, PhD, Sivasubramanian Baskar, PhD, Erika Cook, BA, Inhye E. Ahn, MD, Sarah E. M. Herman, PhD, Christoph Rader, PhD, Adrian Wiestner, MD

Blood (2017) 130 (Supplement 1): 799.

https://doi.org/10.1182/blood.V130.Suppl_1.799.799

Published: 2017

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways

Sarah E. M. Herman, PhD, Delong Liu, PhD, Dan A. Landau, MD PhD, Clare Sun, MD, Mohammed Farooqui, Catherine J Wu, MD, Adrian Wiestner, MDPhD

Blood (2016) 128 (22): 189.

https://doi.org/10.1182/blood.V128.22.189.189

Published: 2016

Journal Articles

Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Erin M. McAuley, BS, Deanna H. Wong, BS, Clare Sun, MD, Delong Liu, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 313.

https://doi.org/10.1182/blood.V126.23.313.313

Published: 2015

Journal Articles

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Arnau Montraveta, BS, Carsten U Niemann, MD PhD, Helena Mora-Jensen, PhD, Michael Gulrajani, BS, Fanny Krantz, Bonnie K. Harrington, DVM, Todd Covey, Brian J Lannutti, PhD, Raquel Izumi, PhD, Roger G Ulrich, PhD, John C. Byrd, MD, Adrian Wiestner, MD PhD, Amy J. Johnson, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2920.

https://doi.org/10.1182/blood.V126.23.2920.2920

Published: 2015

Journal Articles

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

Layla M Saleh, MD, Weixin Wang, PhD, Sarah E. M. Herman, PhD, Mohammed Farooqui, DO, Clare Sun, MD, Emily Barber, B.S., Meghan Corrigan-Cummins, B.S., Nakhle Saba, MD, Hasan Awad, MD, PhD, Adrian Wiestner, MD PhD, Katherine R. Calvo, MD, PhD

Blood (2015) 126 (23): 487.

https://doi.org/10.1182/blood.V126.23.487.487

Published: 2015

Journal Articles

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 1936.

https://doi.org/10.1182/blood.V124.21.1936.1936

Published: 2014

Journal Articles

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Nakhle Saba, MD, Delong Liu, PhD, Sarah E. M. Herman, PhD, Cliona Grant, MD, Kieron Dunleavy, MD, Stefania Pittaluga, Wyndham Wilson, MD PhD, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 2991.

https://doi.org/10.1182/blood.V124.21.2991.2991

Published: 2014

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

Journal Articles

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Sarah E. M. Herman, PhD, Jade Jones, Rashida Z. Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 604.

https://doi.org/10.1182/blood.V122.21.604.604

Published: 2013

Journal Articles

Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NFκB Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma

Nakhle S Saba, MD, Delong Liu, PhD, Sarah E. M. Herman, PhD, Cliona Grant, MD, Kieron Dunleavy, MD, Stefania Pittaluga, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 82.

https://doi.org/10.1182/blood.V122.21.82.82

Published: 2013

NARROW

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Integrated Genomic and Proteomic Analysis of Murine CLL-like Cells Reveals SF3B1 Mutation to Impact DNA Damage Response and BCR Signaling

Durable Responses to Single-Agent Ibrutinib in Monoallelic—but Not in Biallelic— TP53 Aberrated Patients with Chronic Lymphocytic Leukemia

Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib

Transcriptome Analysis of the Lymph Node Microenvironment in Chronic Lymphocytic Leukemia

Activity of CD19/CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways

Ibrutinib Inhibits Both B-Cell Receptor and Toll-like Receptor Signaling in Chronic Lymphocytic Leukemia

The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NFκB Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only